The Food and Drug Administration Bans Sale of Many Antibacterial Soaps, Saying Risks Outweigh Benefits
The Food and Drug Administration banned the sale of soaps containing certain antibacterial chemicals on Friday, saying industry had failed to prove they were safe to use over the long term or more effective than using ordinary soap and water.
It is important that people with disabilities and their family members
make plans to protect themselves in the event of disasters. In addition,
first responders need to know how to work with people with disabilities
to evacuate them safely and quickly. Emergency planners must ensure
that shelters are accessible to people with a variety of disabilities. The Centers for Disease Control and Prevention can help you get ready.
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease (SSc-ILD)
Ingelheim today announced that the European Commission (EC) and U.S.
Food and Drug Administration (FDA) have granted Orphan Drug Designation
to nintedanib for the treatment of systemic sclerosis (SSc, also known
as scleroderma), including the associated interstitial lung disease
Persons with Systemic Sclerosis Needed for Research Study
Researchers from the
Universities of New Mexico and Michigan and the Medical University of South
Carolina are seeing participants for a study to evaluate a self-management program for people with systemic
sclerosis. For more information about the study and eligibility
requirements please contact Jennifer Serrano at email@example.com
STRATUS Clinical Research Study Looking for Patients with Systemic Sclerosis that Affects the Lungs
A clinical research study is looking at an investigational medication that
may slow the development of lung fibrosis (inflammation and scarring)
associated with systemic sclerosis (SSc). To help determine the safety
and effectiveness of the investigational medication, they are looking for
people who have SSc-associated interstitial lung disease (SSc-ILD) that
affects the lungs (SSc-ILD) to take part in the study. For more information about the study and eligibility requirements please contact Courtney Kinsey at firstname.lastname@example.org or 214.818.7899.
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
The Scleroderma Foundation is a qualified national nonprofit operating under 501(c)(3) status. The foundation’s federal tax identification number is 52-1375827. Our primary goal is to raise funds for our three-fold mission of support, education and research. The foundation has 20 active chapters and 160 support groups across the country.